Sunovion crowds a new group of Parkinson’s drugs, with uncertain sales prospects

Sunovion crowds a new group of Parkinson’s drugs, with uncertain sales prospects
Kynmobi has become the fourth drug the FDA has approved since late 2018 for the "off" episodes Parkinson's disease patients experience. The coronavirus pandemic may complicate an already challenging ... read more
Source: Bing NewsPublished on 2020-05-22